400 related articles for article (PubMed ID: 30107620)
1. [Duodenale levodopa and apomorphine infusion for motor complications in advanced Parkinson's disease].
Antonini A; Jost WH
Fortschr Neurol Psychiatr; 2018 Sep; 86(S 01):S5-S9. PubMed ID: 30107620
[TBL] [Abstract][Full Text] [Related]
2. Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease.
Antonini A; Nitu B
J Neural Transm (Vienna); 2018 Aug; 125(8):1131-1135. PubMed ID: 30006821
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
Deleu D; Hanssens Y; Northway MG
Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
[TBL] [Abstract][Full Text] [Related]
4. [Treatment possibilities in advanced Parkinson's disease].
Takáts A; Nagy H; Radics P; Tóth A; Tamás G
Ideggyogy Sz; 2013 Nov; 66(11-12):365-71. PubMed ID: 24555235
[TBL] [Abstract][Full Text] [Related]
5. On demand therapy for Parkinson's disease patients: Opportunities and choices.
Hauser RA; LeWitt PA; Comella CL
Postgrad Med; 2021 Sep; 133(7):721-727. PubMed ID: 34082655
[TBL] [Abstract][Full Text] [Related]
6. Motor features and response to oral levodopa in patients with Parkinson's disease under continuous dopaminergic infusion or deep brain stimulation.
Elia AE; Dollenz C; Soliveri P; Albanese A
Eur J Neurol; 2012 Jan; 19(1):76-83. PubMed ID: 21645174
[TBL] [Abstract][Full Text] [Related]
7. Continuous dopaminergic stimulation in Parkinson's disease.
Obeso JA; Luquin MR; Vaamonde J; Grandas F; Martinez Lage JM
Can J Neurol Sci; 1987 Aug; 14(3 Suppl):488-92. PubMed ID: 3676922
[TBL] [Abstract][Full Text] [Related]
8. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329
[TBL] [Abstract][Full Text] [Related]
9. Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's disease.
Clarke CE; Worth P; Grosset D; Stewart D
Parkinsonism Relat Disord; 2009 Dec; 15(10):728-41. PubMed ID: 19805000
[TBL] [Abstract][Full Text] [Related]
10. Use of apomorphine in Parkinson's disease.
Stocchi F
Neurol Sci; 2008 Dec; 29 Suppl 5():S383-6. PubMed ID: 19381769
[TBL] [Abstract][Full Text] [Related]
11. Treatments for Parkinson disease--past achievements and current clinical needs.
Poewe W
Neurology; 2009 Feb; 72(7 Suppl):S65-73. PubMed ID: 19221317
[TBL] [Abstract][Full Text] [Related]
12. Current management of motor fluctuations in patients with advanced Parkinson's disease treated chronically with levodopa.
Melamed E; Zoldan J; Galili-Mosberg R; Ziv I; Djaldetti R
J Neural Transm Suppl; 1999; 56():173-83. PubMed ID: 10370911
[TBL] [Abstract][Full Text] [Related]
13. Medical and surgical management of advanced Parkinson's disease.
Antonini A; Moro E; Godeiro C; Reichmann H
Mov Disord; 2018 Jul; 33(6):900-908. PubMed ID: 29570862
[TBL] [Abstract][Full Text] [Related]
14. [Experience with continuous levodopa enteral infusion (Duodopa(®)) in patients with advanced Parkinson's disease in a secondary level hospital].
Santos-García D; Macías M; Llaneza M; Fuster-Sanjurjo L; Echarri-Piudo A; Belmonte S; Blanco S
Neurologia; 2010; 25(9):536-43. PubMed ID: 21093702
[TBL] [Abstract][Full Text] [Related]
15. [Device-aided therapies in advanced Parkinson's disease].
Timofeeva AA
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(12):54-60. PubMed ID: 28139627
[TBL] [Abstract][Full Text] [Related]
16. Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson's disease.
Wenning GK; Bösch S; Luginger E; Wagner M; Poewe W
Adv Neurol; 1999; 80():545-8. PubMed ID: 10410769
[No Abstract] [Full Text] [Related]
17. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
Manson AJ; Turner K; Lees AJ
Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062
[TBL] [Abstract][Full Text] [Related]
18. [Shifting to subcutaneous infusion of apomorphine in advanced Parkinson's disease patients on an out-patient basis: experience and recommendations].
Castaño B; Mateo D; Giménez-Roldán S
Neurologia; 2007 Apr; 22(3):133-7. PubMed ID: 17364250
[TBL] [Abstract][Full Text] [Related]
19. Use of advanced therapies for Parkinson's disease in Norway.
Ezat B; Pihlstrøm L; Aasly J; Tysnes OB; Egge A; Dietrichs E
Tidsskr Nor Laegeforen; 2017 May; 137(9):619-623. PubMed ID: 28468476
[TBL] [Abstract][Full Text] [Related]
20. [The concept of continuous dopaminergic stimulation in the treatment of late stages of Parkinson's disease].
Titova NV; Katunina EA
Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(12):105-12. PubMed ID: 24596973
[No Abstract] [Full Text] [Related]
[Next] [New Search]
